Acadia Pharmaceuticals (ACAD) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $3.16B
- As of Nov 17, 2026
- P/E
- 8.72x
- Trailing twelve months
- P/B
- 2.28x
- Latest reported equity
- P/S
- 2.63x
- Trailing twelve months
- ROE
- 26.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $3.16B
- As of Nov 17, 2026
- P/E
- 8.72x
- Trailing twelve months
- P/B
- 2.28x
- Latest reported equity
- P/S
- 2.63x
- Trailing twelve months
- ROE
- 26.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
8.72x
P/B
2.28x
P/S
2.63x
Earnings and dividend metrics▾
Earnings
EPS
$2.10
Earnings per share
BPS
$8.02
Book value per share
ROE
26.2%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.10 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $8.02 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 26.2%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 22.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $279M+22.6%
$250M
Jul–Sep '24
$279M
Jul–Sep '25
$342M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 5, 2026.
- Earnings per share decreased 26.2% from the same quarter a year earlier.
- Revenue increased 22.6% from the same quarter a year earlier.
- Operating income increased 100.0% from the same quarter a year earlier.
- Net income decreased 25.0% from the same quarter a year earlier.
Filed Nov 5, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Oct 30, 2026Open-market sale3,321 shares · $69KAvg. price $20.8871,322 shares held after
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Oct 15, 2026Grant or award6,815 shares · $0Avg. price $074,643 shares held after
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 6, 2026Open-market sale14,292 shares · $418KAvg. price $29.2194
Show 2 price lots
- 9,292 shares × $29.3375$273K
- 5,000 shares × $29$145K
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 6, 2026Option exercise14,292 shares · $255KAvg. price $17.8482,120 shares held after
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 5, 2026Open-market sale5,849 shares · $170KAvg. price $29.002967,828 shares held after
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 5, 2026Option exercise5,849 shares · $104KAvg. price $17.8473,677 shares held after
- Thompson Elizabeth H.Z.EVP, Head of Research & Dev · Jul 30, 2026Open-market sale16,558 shares · $433KAvg. price $26.1301
Show 2 price lots
- 16,508 shares × $26.13$431K
- 50 shares × $26.17$1K
- Thompson Elizabeth H.Z.EVP, Head of Research & Dev · Jul 29, 2026Option exercise32,272 shares35,552 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Acadia Pharmaceuticals (ACAD) stock information
NASDAQ
Acadia Pharmaceuticals (ACAD) is listed on NASDAQ. Its market capitalization is about $3.2B. On trailing-twelve-month earnings the P/E ratio is 8.72, and the P/B ratio is 2.28. Return on equity is 26.2%. These figures are computed in-house from official filings and are reference information only.
Acadia Pharmaceuticals — frequently asked questions
- What is the P/E ratio of Acadia Pharmaceuticals (ACAD)?
- On a trailing-twelve-month basis, ACAD trades at a P/E ratio of 8.72. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Acadia Pharmaceuticals?
- ACAD has a market capitalization of about $3.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.